Evidence map›Paper›PMID 30416604›Full record

ArticleCancer nanotechnology2018

C

Larysa M Skivka, Svitlana V Prylutska, Mariia P Rudyk, Nataliia M Khranovska, Ievgeniia V Opeida, Vasyl V Hurmach, Yuriy I Prylutskyy, Leonid F Sukhodub, Uwe Ritter

Open access · goldAbstract read
In one paragraph

Article in Cancer nanotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. CNanomedicine (London, England) · 2025
    Article
  3. Review
  4. Article
  5. Water-soluble pristine CBMC musculoskeletal disorders · 2023
    Article
  6. Article
  7. Article
  8. CScientific reports · 2021
    Article
  9. Review
  10. Article
  11. Effects of Pristine CDigestive diseases and sciences · 2020
    Article
  12. CPharmaceutics · 2019
    Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Larysa M Skivka1Taras Shevchenko National University of Kyiv, 64 Volodymyrska str., Kiev, 01601 Ukraine.
Svitlana V Prylutska1Taras Shevchenko National University of Kyiv, 64 Volodymyrska str., Kiev, 01601 Ukraine.
Mariia P Rudyk1Taras Shevchenko National University of Kyiv, 64 Volodymyrska str., Kiev, 01601 Ukraine.
Nataliia M Khranovska2National Cancer Institute, 33/43 Lomonosova str., Kiev, 03022 Ukraine.
Ievgeniia V Opeida1Taras Shevchenko National University of Kyiv, 64 Volodymyrska str., Kiev, 01601 Ukraine.
Vasyl V Hurmach1Taras Shevchenko National University of Kyiv, 64 Volodymyrska str., Kiev, 01601 Ukraine.
Yuriy I Prylutskyy1Taras Shevchenko National University of Kyiv, 64 Volodymyrska str., Kiev, 01601 Ukraine.
Leonid F Sukhodub3Sumy State University, 2 Rymskogo-Korsakova str., Sumy, 40007 Ukraine.
Uwe Ritter4Institute of Chemistry and Biotechnology, Technical University of Ilmenau, Weimarer str. 25, 98693 Ilmenau, Germany.ORCID 0000-0002-9315-4863
Taras Shevchenko National University of Kyiv · UANational Cancer Institute · UASumy State University · UATechnische Universität Ilmenau · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundC

methodsAnalysis of the metabolic profile of phagocytes exposed to C

resultsCytotoxic action as well as the pro-oxidant effect of C

conclusionsThe antineoplastic effect of C

Indexed as

Anticancer drugsC60 fullereneComputer simulationNanocomplexesROS generationTransformed monocytes

Identifiers

PMID30416604
PMCPMC6208740
OpenAlexW2898696079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.